XOMA Royalty Corporation (NASDAQ: XOMAP, common stock: XOMA) is a biotech royalty aggregator that plays a unique role in the biotech industry by acquiring economic rights to streams of future milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company was originally founded in 1981 as ...XOMA Royalty Corporation (NASDAQ: XOMAP, common stock: XOMA) is a biotech royalty aggregator that plays a unique role in the biotech industry by acquiring economic rights to streams of future milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company was originally founded in 1981 as XOMA Corporation, a traditional biotech company focused on developing and licensing its own drugs. In 2017, under a strategic transformation, it pivoted to become a royalty aggregator, and in July 2024 it was renamed XOMA Royalty Corporation to reflect its new focus. The company is headquartered at 2200 Powell Street, Emeryville, California, and is listed on NASDAQ, with the preferred stock XOMAP trading as an ADR-like security.
XOMA Royalty's business model involves investing in a diversified portfolio of biotech assets, ranging from early-stage (Phase 1 and 2) candidates to late-stage and commercial products. It acquires royalty and milestone revenue streams by licensing its assets to other biotech and pharma companies, acting as a financial partner rather than a drug developer. The portfolio includes over 120 assets, with seven commercial products as of 2024, providing a steady stream of potential milestone payments and royalties. The company's revenue is primarily derived from these royalty streams, with a gross profit margin of 94.3% and a net profit margin of 123.3% (though these figures may be distorted by one-time gains). Key financial metrics include a market cap of approximately $301 million, an enterprise value of $331.6 million, and a price-to-earnings ratio of 15.1. The company has a moderate debt level, with a debt-to-equity ratio of 1.1, and a dividend yield of 8.6%, reflecting its attractive income potential.
The company is led by CEO Owen Patrick Hughes, who also serves as a key executive, with a team of only 14 full-time employees, indicating a lean and highly specialized operation. Other key executives include CFO Jeffrey Trigilio and Chief Investment Officer Brad Sitko. XOMA Royalty's investor relations highlight its role in helping biotech companies achieve their goals by providing capital in exchange for economic rights, and in 2024, the company announced that it would be acquired by Ligand Pharmaceuticals, a transaction that would expand Ligand's royalty portfolio to over 200 assets. This acquisition underscores XOMA's value as a royalty aggregator. Despite its small team, XOMA Royalty has a significant impact on the biotech sector, and its financial performance, including a price-to-book ratio of 2.6 and a return on equity of 32.4%, reflects effective capital deployment. With a focus on both commercial assets and early-stage candidates, XOMA Royalty continues to seek new opportunities to acquire royalty streams, positioning itself as a niche player in the biotech financial landscape.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.
TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).
$52.1M
+83.1%
+760.2%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.
$31.7M
+329.4%
-26.8%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.
+94.3%
-5.0%
-7.3%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).
+21.8%
+115.6%
-102.6%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.
+60.8%
+225.3%
-91.5%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.
$2.9M
+120.9%
+209.8%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.
+5.5%
+111.4%
+112.8%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.
126.5%
-13.0%
-12.7%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.
3.37x
-34.7%
+6.6%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.
Operator: Good day, everyone. My name is Kahalani, and I will be your conference operator today. At this time, I would like to welcome you to the XOMA Royalty 2025 Financial Results and Business Highlights Investor Call. [Operator Instructions] At this time, I'd like to turn the call over to Juliane Snowden, Investor Relations.
Juliane Snowden: Good morning, everyone, and welcome to the XOMA Royalty Fourth Quarter and Full Year 2025 Earnings Call. Earlier today, we issued our financial results press release, which is available in the Investor Relations section of our website at www.xoma.com. A replay of this call will be available on our website following the webcast. Joining me today are Owen Hughes, Chief Executive Officer; Brad Sitko, Chief Investment Officer; and Jeff Trigilio, Chief Financial Officer. During today's call, we will review our 2025 financial results, discuss recent business development activity and portfolio updates, and provide commentary on key upcoming catalysts. After our prepared remarks, we will open the call for questions. Before we begin, I would like to remind everyone that statements made during this call that are not historical facts may be considered forward-looking statements within the meaning of federal securities laws. These statements are based on our current expectations and are subject to risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those described or implied in these statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Form 10-K for a discussion of these and other risks. XOMA Royalty undertakes no obligation to update forward-looking statements, except as required by law. And with that, I'll turn the call over to Owen.
Owen Hughes: Thank you very much, Juliane, and good morning, everyone. 2025 was a foundational year for XOMA Royalty as we continue to execute on our strategy of building a diversified portfolio of biotechnology royalty and milestone assets. We are approaching the inflection point when expected cash flows from our royalty receipts alone should cover the core operating costs of the company. Through both traditional royalty and milestone acquisitions as well as innovative transactions, we enhanced the company's prospects by adding 22 assets to the XOMA Royalty portfolio in 2025 in addition to the acquisition of 2 platform technologies that we hope to be able to out-license in order to generate future royalties and milestones. Furthermore, total portfolio receipts surpassed $50 million, including royalty receipts of $34 million, which grew 68% from fiscal year 2024. By maintaining a lean operating structure, we achieved positive cash flow from operations, and we were able to return $16 million of capital through opportunistic share buybacks in 2025, retiring more than 5% of our common stock outstanding. On a go-forward basis, we anticipate maintaining a disciplined approach …
